Нарушение речи при сосудистых и нейродегенеративных заболеваниях: возможности медикаментозной и немедикаментозной терапии


DOI: https://dx.doi.org/10.18565/pharmateca.2020.3.38-49

Е.Е. Васенина, О.С. Левин

Российская медицинская академия непрерывного профессионального образования, Москва, Россия
Нарушения речи служат частым проявлением как сосудистых, так и нейродегенеративных заболеваний головного мозга. Наличие афазии после инсульта определяет плохой прогноз восстановления в целом, значительно снижает качество жизни, что требует поиска оптимальных путей ее коррекции. При нейродегенеративной патологии нарушения речи чаще всего рассматриваются в аспекте первичных прогрессирующих афазий, при том что речевой дефект встречается гораздо чаще и типичен практически для всех форм дегенерации. В статье представлен комплексный обзор эффективности различных фармакологических и немедикаментозных методов терапии нарушений речи при сосудистых и нейродегенеративных заболеваниях. Предложен новый подход к классификации речевых нарушений при нейродегенеративной патологии ЦНС.
Ключевые слова: инсульт, афазия, нейродегенеративные заболевания, нарушения речи, классификация, реабилитация, транскраниальная стимуляция

Литература


1. Doogan C., Dignam J., Copland D., Leff A. Aphasia Recovery: When, How and Who to Treat? Curr Neurol Neurosci Rep. 2018;18(12):90. Doi: 10.1007/s11910-018-0891-x.


2. Lam J.M., Wodchis W.P. The relationship of 60 disease diagnoses and 15 conditions to preference-based health-related quality of life in Ontario hospital-based long-term care residents. Med Care. 2010;48(4):380–87. Doi: 10.1097/MLR.0b013e3181ca2647.


3. Best W., Greenwood A., Grassly J., Hickin J. Bridging the gap: can impairment-based therapy for anomia have an impact at the psycho-social level? Int J Lang Commun Disord. 2008;43(4):390–407. Doi: 10.1080/13682820701608001.


4. Bakas T., Kroenke K., Plue L.D., et al. Outcomes among family caregivers of aphasic versus nonaphasic stroke survivors. Rehabil Nurs. 2006;31(1):33–42. Doi: 10.1002/j.2048-7940.2006.tb00008.x.


5. Broome L.J., Battle C.E., Lawrence M., et al. Cognitive Outcomes following Thrombolysis in Acute Ischemic Stroke: A Systematic Review. J Stroke Cerebrovasc Dis. 2016;25(12):2868–75. Doi: 10.1016/j.jstrokecerebrovasdis.2016.07.048.


6. Menichelli A., Furlanis G., Sartori A., et al. Thrombolysis’ benefits on early post-stroke language recovery in aphasia patients. J Clin Neurosci. 2019;70:92–5. Doi: 10.1016/j.jocn.2019.08.064.


7. Furlanis G., Ridolfi M., Polverino P., et al. Early Recovery of Aphasia through Thrombolysis: The Significance of Spontaneous Speech. J Stroke Cerebrovasc Dis. 2018;27(7):1937–48. Doi: 10.1016/j.jstrokecerebrovasdis.2018.02.043.


8. Martins I.P., Fonseca J., Morgado J., et al. Language improvement one week after thrombolysis in acute stroke. Acta Neurol Scand. 2017;135(3):339–45. Doi: 10.1111/ane.12604.


9. Denier C., Chassin O., Vandendries C., et al. Thrombolysis in Stroke Patients with Isolated Aphasia. Cerebrovasc Dis. 2016;41(3–4):163–69. Doi: 10.1159/000442303.


10. Saxena S., Hillis A.E. An update on medications and noninvasive brain stimulation to augment language rehabilitation in post-stroke aphasia. Expert Rev Neurother. 2017;17(11):1091–107. Doi: 10.1080/14737175.2017.1373020.


11. Васенина Е.Е., Левин О.С. Фармакотерапия постинсультной афазии. СТПН. 2018. № 2.


12. Knecht S., Breitenstein C., Bushuven S., et al. Levodopa: faster and better word learning in normal humans. Ann Neurol. 2004;56(1):20–6.


13. Ozeren A., Sarica Y., Mavi H., et al. Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. Acta Neurol Belg. 1995;95(4):235–38.


14. Bragoni M., Altieri M., Di Piero V., et al. Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke. Neurol Sci. 2000;21(1):19–22.


15. Sabe L., Salvarezza F., Garcia Cuerva A., et al. A randomized, doubleblind, placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology. 1995;45(12):2272–74.


16. Ashtary F., Janghorbani M., Chitsaz A., et al. A randomized, doubleblind trial of bromocriptine efficacy in nonfluent aphasia after stroke. Neurology. 2006;66(6):914–16.


17. Zhang X., Shu B., Zhang D., et al. The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia. CNS Neurol Disord Drug Targets. 2018;17(7):509–21. Doi: 10.2174/1871527317666180706143051.


18. Arciniegas D.B., Frey K.L., Anderson C.A., et al. Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy. Brain Inj. 2004;18(12):1309–18.


19. Barrett A.M., Eslinger P.J. Amantadine for adynamic speech: possible benefit for aphasia? Am J Phys Med Rehabil. 2007;86(8):605–12.


20. Seniow J., Litwin M., Litwin T., et al. New approach to the rehabilitation of post-stroke focal cognitive syndrome: effect of levodopa combined with speech and language therapy on functional recovery from aphasia. J Neurol Sci. 2009;283(1–2):214–18.


21. Leemann B., Laganaro M., Chetelat-Mabillard D., et al. Crossover trial of subacute computerized aphasia therapy for anomia with the addition of either levodopa or placebo. Neurorehabil Neural Repair. 2011;25(1):43–7.


22. Das U.K., Uddin M.J., Bhattacharjee M., et al. Motor Outcome of Stroke Patients with Low Dose Levodopa Therapy. Mymensingh Med J. 2019;28(4):762–66.


23. Acler M., Manganotti P. Role, indications and controversies of levodopa administration in chronic stroke patients. Eur J Phys Rehabil Med. 2013;49(2):243–49.


24. Breitenstein C., Korsukewitz C., Baumgartner A., et al. L-dopa does not add to the success of high-intensity language training in aphasia. Restor Neurol Neurosci. 2015;33(2):115–20.


25. Sarter M., Hasselmo M.E., Bruno J.P., et al. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Rev. 2005;48(1):98–111.


26. Yoon S.Y., Kim J.K., An Y.S., et al. Effect of donepezil on Wernicke Aphasia after bilateral middle cerebral artery infarction: subtraction analysis of brain F-18 fluorodeoxyglucose positron emission tomographic images. Clin Neuropharmacol. 2015;38(4):147–50.


27. Berthier M.L., Hinojosa J., Martin M.C., et al. Open-label study of donepezil in chronic poststroke aphasia. Neurology. 2003;60 (7):1218–19.


28. Pashek G., Bachman D. Cognitive, linguistic, and motor speech of donepezil hydrochloride in a patient with stroke-related aphasia and apraxia of speech. Brain and Language. 2001;87(1):179–80.


29. Berthier M.L., Green C., Higueras C., et al. A randomized, placebocontrolled study of donepezil in poststroke aphasia. Neurology. 2006;67(9):1687–89.


30. Chen Y., Li Y.S., Wang Z.Y., et al. The efficacy of donepezil for poststroke aphasia: a pilot case control study. Zhonghua Nei Ke Za Zhi. 2010;49(2):115–18.


31. Hong J.M., Shin D.H., Lim T.S., et al. Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry. 2012;83(7):675–80.


32. Jacobs D.H., Shuren J., Gold M., et al. Physostigmine pharmacotherapy for anomia. Neurocase. 1996;2(2):83–91.


33. Jitsuki S., Takemoto K., Kawasaki T., et al. Serotonin mediates crossmodal reorganization of cortical circuits. Neuron. 2011;69(4):780–92.


34. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology. 2008;33(1):73–83.


35. Kimura M., Robinson R.G., Kosier J.T. Treatment of cognitive impairment after poststroke depression: a double-blind treatment trial. Stroke. 2000;31(7):1482–86.


36. Li W.L., Cai H.H., Wang B., et al. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res. 2009;87 (1):112–22.


37. Laska A.C., von Arbin M., Kahan T., et al. Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. Cerebrovasc Dis. 2005;19(2):125–32.


38. Martin H.G., Wang Y.T. Blocking the deadly effects of the NMDA receptor in stroke. Cell. 2010;140(2):174–76.


39. Berthier M.L., Green C., Lara J.P., et al. Memantine and constraintinduced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65(5):577–85.


40. Barbancho M.A., Berthier M.L., Navas-Sánchez P., et al. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. Brain and Language. 2015;145–46:1–10.


41. Huber W., Willmes K., Poeck K., et al. Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebocontrolled pilot study. Arch Phys Med Rehabil. 1997;78(3):245–50.


42. Enderby P., Broeckx J., Hospers W., et al. Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebocontrolled study. Clin Neuropharmacol. 1994;17(4):320–31.


43. Zhang J., Wei R., Chen Z., Luo B. Piracetam for aphasia in post-stroke patients: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs 2016;30:575–87.


44. Tsikunov S.G., Belokoskova S.G. Psychophysiological analysis of the influence of vasopressin on speech in patients with post-stroke aphasias. Span J Psychol. 2007;10(1):178–188.


45. Jianu D.C., Muresanu D.F., Bajenaru O., et al. Cerebrolysin adjuvant treatment in Broca’s aphasics following first acute ischemic stroke of the left middle cerebral artery


46. Shishkova V.N., Zotova L.I., Maljukova N.G., et al. An assessment of cerebrolysin effect on BDNF level in patients with post stroke aphasia depending on carbohydrate metabolism disorders Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(5):57–63. Doi: 10.17116/jnevro20151155157-63.


47. Fridriksson J., Elm J., Stark B.C., et al. BDNF genotype and tDCS interaction in aphasia treatment. Brain Stimul. 2018;11(6):1276–81. Doi: 10.1016/j.brs.2018.08.009.


48. de Boer R.G.A., Spielmann K., Heijenbrok-Kal M.H.,et al. The Role of the BDNF Val66Met Polymorphism in Recovery of Aphasia After Stroke. Neurorehabil Neural Repair. 2017;31(9):851–57. Doi: 10.1177/1545968317723752.


49. Fridriksson J., Elm J., Stark B.C., et al. BDNF genotype and tDCS interaction in aphasia treatment. Brain Stimul. 2018;11(6):1276–81. Doi: 10.1016/j.brs.2018.08.009.


50. Cohen L., Chaaban B., Habert M.O. Transient improvement of aphasia with zolpidem. N Engl J Med. 2004;350(9):949–50.


51. Beversdorf D.Q., Sharma U.K., Phillips N.N., et al. Effect of propranolol on naming in chronic Broca’s aphasia with anomia. Neurocase. 2007;13(4):256–59.


52. Cahana-Amitay D., Albert M.L., Pyun S.B., et al. Language as a stressor in aphasia. Aphasiology. 2011;25(5):593–614.


53. Breitenstein C., Grewe T., Flöel A., et al. Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting


54. Watila M.M., Balarabe S.A. Factors predicting post-stroke aphasia recovery. J Neurol Sci. 2015;352(1–2):12–8. Doi: 10.1016/j.jns.2015.03.020.


55. Varley R., Cowell P.E., Dyson L., et al. Self-Administered Computer Therapy for Apraxia of Speech: Two-Period Randomized Control Trial With Crossover. Stroke. 2016;47(3):822–28. Doi: 10.1161/STROKEAHA.115.011939.


56. Haldin C., Acher A., Kauffmann L., et al. Speech recovery and language plasticity can be facilitated by Sensori-Motor Fusion training in chronic non-fluent aphasia. A case report study. Clin Linguist Phon. 2018;32(7):595–621. Doi: 10.1080/02699206.2017.1402090.


57. Fridriksson J., Rorden C., Elm J., et al. Transcranial Direct Current Stimulation vs Sham Stimulation to Treat Aphasia After Stroke: A Randomized Clinical Trial. JAMA Neurol. 2018;75(12):1470–76. Doi: 10.1001/jamaneurol.2018.2287.


58. Biou E., Cassoudesalle H., Cogné M., et al. Transcranial direct current stimulation in post-stroke aphasia rehabilitation: A systematic review. Ann Phys Rehabil Med. 2019;62(2):104–21. Doi: 10.1016/j.rehab.2019.01.003.


59. Elsner B., Kugler J., Pohl M, Mehrholz J.. Transcranial direct current stimulation (tDCS) for improving aphasia in adults with aphasia after stroke. Cochrane Database Syst Rev. 2019;5(5):CD009760. Published 2019. May 21. Doi:10.1002/14651858.CD009760.pub4.


60. Kapoor A. Repetitive transcranial magnetic stimulation therapy for post-stroke non-fluent aphasia: A critical review. Top Stroke Rehabil. 2017;24(7):547–53. Doi: 10.1080/10749357.2017.1331417.


61. Versace V., Schwenker K., Langthaler P.B., et al. Facilitation of Auditory Comprehension After Theta Burst Stimulation of Wernicke’s Area in Stroke Patients: A Pilot Study. Front Neurol. 2020;10:1319. Published 2020 Jan 8. Doi: 10.3389/fneur.2019.01319.


62. Van Der Meulen I., Van De Sandt-Koenderman M.W., Heijenbrok M.H., et al. Melodic Intonation Therapy in Chronic Aphasia: Evidence from a Pilot Randomized Controlled Trial. Front Hum Neurosci. 2016;10:533. Doi: 10.3389/fnhum.2016.00533.


63. Haro-Martínez A.M., Lubrini G., Madero-Jarabo R.,et al. Melodic intonation therapy in post-stroke nonfluent aphasia: a randomized pilot trial. Clin Rehabil. 2019;33(1):44–53. Doi: 10.1177/0269215518791004.


64. Cortese M.D., Riganello F., Arcuri F., et al. Rehabilitation of aphasia: application of melodic-rhythmic therapy to Italian language. Front Hum Neurosci. 2015;9:520. Doi: 10.3389/fnhum.2015.00520.


65. Tabei K.I., Satoh M., Nakano C., et al. Improved Neural Processing Efficiency in a Chronic Aphasia Patient Following Melodic Intonation Therapy: A Neuropsychological and Functional MRI Study. Front Neurol. 2016;7:148. Doi: 10.3389/fneur.2016.00148.


66. Bitan T., Simic T., Saverino C. et al. Changes in Resting-State Connectivity following Melody-Based Therapy in a Patient with Aphasia. Neural Plast. 2018;2018:1–13. Doi: 10.1155/2018/6214095.


67. Vibrac C., Avias A., François P., et al. Charlie Chaplin and gesture training in severe aphasia: a randomized double-blind single-case experimental design. Ann Phys Rehabil Med. 2020. Doi: 10.1016/j.rehab.2019.12.010.


68. Васенина Е.Е., Левин О.С. Первичные прогрессирующие афазии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;114(6):3–12.


69. Marshall C.R., Hardy C.J.D., Volkmer A., et al. Primary progressive aphasia: a clinical approach. J Neurol. 2018;265(6):1474–90. Doi: 10.1007/s00415-018-8762-6.


70. Kishi T., Matsunaga S., Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883–85. Doi: 10.2147/NDT.S94430.


71. Rockenstein E., Ubhi K., Mante M., et al. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies. BMC Neurosci. 2015;16:85. Doi: 10.1186/s12868-015-0218-7.


72. Henry M.L., Hubbard H.I., Grasso S.M., et al. Treatment for Word Retrieval in Semantic and Logopenic Variants of Primary Progressive Aphasia: Immediate and Long-Term Outcomes. J Speech Lang Hear Res. 2019;62(8):2723–49. Doi: 10.1044/2018_JSLHR-L-18-0144.


73. Cadório I., Lousada M., Martins P., Figueiredo D. Generalization and maintenance of treatment gains in primary progressive aphasia (PPA): a systematic review. Intern J Language Communication Disord. 201752(5), 543–60. Doi: https://doi.org/10.1111/1460-6984.12310.


74. Byeon H. Meta-Analysis on the Effects of Transcranial Direct Current Stimulation on Naming of Elderly with Primary Progressive Aphasia. Int J Environ Res Public Health. 2020;17(3):1095. Doi: 10.3390/ijerph17031095.


75. Cotelli M., Manenti R., Ferrari C., et al. Effectiveness of language training and non-invasive brain stimulation on oral and written naming performance in Primary Progressive Aphasia: A meta-analysis and systematic review. Neurosci Biobehav Rev. 2020;108:498–525. Doi: 10.1016/j.neubiorev.2019.12.003.


76. Васенина Е.Е., Левин О.С. Гетерогенность речевых нарушений при болезни Паркинсона: возможности классификации, диагностики и терапии. Медицинский совет. 2020;(2):55–66.


77. Ramig, L., Halpern, A., Spielman, J., et al. Speech treatment in Parkinson’s disease: Randomized controlled trial (RCT). Movement disorders: official journal of the Movement Disorder Society. 2018;33(11):777–91. Doi: https://doi.org/10.1002/mds.27460.


Об авторах / Для корреспонденции


Автор для связи: Е.Е. Васенина, к.м.н., доцент, кафедра неврологии, Российская медицинская академия непрерывного профессионального образования, Москва, Россия; e-mail: hel_vas@mail.ru
Адрес: 125993, Россия, Москва, Баррикадная ул., 2/1, стр. 1


ORCID:
Е.Е. Васенина, ORCID: https://orcid.org/0000-0002-2600-0573  
О.С. Левин, ORCID: https://orcid.org/0000-0003-3872-5923 


Бионика Медиа